Systematic literature review of health economic models developed for multiple myeloma to support future analyses

Choon-Quinones, Mimi; Zelei, Tamás; Németh, Bertalan; Tóth, Manna; Jia, Xiao Yang; Barnett, Mike; Keown, Paul; Durie, Brian G.M.; Harousseau, Jean‐Luc; Hose, Dirk; Kaló, Zoltán

doi:10.1080/13696998.2022.2144056

Cited by 4 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…для того, чтобы сделать медицинскую помощь таким пациентам более доступной, требуется фармакоэкономическое обоснование применяемых схем фармакотерапии [35]. согласно международным литературным данным, полученным из medline, Scopus, web of Science, pubmed, в настоящее время отсутствуют актуальные сводные данные по оценке экономической эффективности лечения мм [36].…”

Section: результатыunclassified

Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data

Luchinin,

Zhuravleva,

Shelehova

et al. 2024

jour

View full text Add to dashboard Cite

Among hematological diseases, Multiple myeloma (MM) is the second most common malignancy in adults worldwide. In the vast majority of cases, MM remains incurable, despite improvements in progression-free survival and overall survival due to advances in pharmacotherapy, as well as the emergence of innovative drugs in recent years. Unfortunately, this does not prevent patients from relapse and, ultimately, multidrug resistance and poor prognosis. In conditions of limited funding, one of the determining factors for the success of therapy is the cost of treatment. There is a need to conduct a clinical and economic analysis of the use of targeted drugs to determine the most economically feasible treatment option. The purpose of the review is to provide an overview of current and experimental treatments for relapsed/refractory MM (RRMM), with an emphasis on their pharmacoeconomic availability to assist clinicians in their decision-making process. Let's look at the latest data that will help improve approaches to the treatment of this still incurable disease and analyze pharmacoeconomic studies of modern expensive treatment regimens for RRMM in various countries.

show abstract

Section: результатыunclassified

Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data

Luchinin,

Zhuravleva,

Shelehova

et al. 2024

jour

View full text Add to dashboard Cite

show abstract

Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling

Corro Ramos,

Feenstra,

Ghabri

et al. 2024

PharmacoEconomics

View full text Add to dashboard Cite

A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models

Freitag,

Sarri,

et al. 2024

PharmacoEconomics

View full text Add to dashboard Cite

Background and Objective Multiple myeloma is a rare incurable hematological cancer in which most patients relapse or become refractory to treatment. This systematic literature review aimed to critically review the existing economic models used in economic evaluations of systemic treatments for relapsed/refractory multiple myeloma and to summarize how the models addressed differences in the line of therapy and exposure to prior treatment. Methods Following a pre-approved protocol, literature searches were conducted on 17 February, 2023, in relevant databases for models published since 2014. Additionally, key health technology assessment agency websites were manually searched for models published as part of submission dossiers since 2018. Reported information related to model conceptualization, structure, uncertainty, validation, and transparency were extracted into a pre-defined extraction sheet. Results In total, 49 models assessing a wide range of interventions across multiple lines of therapy were included. Only five models specific to heavily pre-treated patients and/or those who were refractory to multiple treatment classes were identified. Most models followed a conventional simple methodology, such as partitioned survival ( n = 28) or Markov models ( n = 9). All included models evaluated specific interventions rather than the whole treatment sequence. Where subsequent therapies were included in the model, these were generally only considered from a cost and resource use perspective. The models generally used overall and progression-free survival as model inputs, although data were often immature. Sensitivity analyses were frequently reported ( n = 41) whereas validation was only considered in less than half ( n = 19) of the models. Conclusions Published economic models in relapsed/refractory multiple myeloma rarely followed an individual patient approach, mainly owing to the higher need for complex data assumptions compared with simpler modeling approaches. As many patients experience disease progression on multiple treatment lines, there is a growing need for modeling complex treatment strategies, leading to more sophisticated approaches in the future. Maintaining transparency, high reporting standards, and thorough analyses of uncertainty are crucial to support these advancements. Supplementary Information The online version contains supplementary material available at 10.1007/s40273-024-01399-3.

show abstract

Systematic literature review of health economic models developed for multiple myeloma to support future analyses

Cited by 4 publications

References 66 publications

Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data

Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data

Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling

A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models

Contact Info

Product

Resources

About